Business
Radiopharm Theranostics tanks on ASX debut – The Australian Financial Review
The paper value of chairman Paul Hopper’s 35.5 per cent stake fell from $54 million to $36 million in just a few hours.
The early stage company does not have revenue from licence arrangements or product sales. It is developing a platform of radiopharmaceutical products for diagnostic and therapeutic cancer treatment.
Shanghai-based NanoMab Technologies is the second-largest…
Continue Reading
-
Noosa News10 hours agoChild, 15, arrested over death of another child, 8, after shocking e-bike crash in Queensland
-
Noosa News9 hours agoLyka Doggie Date Night at Moonlight Cinema
-
Noosa News9 hours agoQueensland Drug and Alcohol Court provides sentencing options – Proctor
-
Business11 hours agoSolid superannuation gains continue to roll in